Indications
Therapeutic Asset Ratings
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
(+)-Vincristine
Large B-Cell Lymphoma
AstraZeneca
P3
BB
(69)
(+)-Vincristine
Richter Transformation
SWOG Cancer Research Network
P3
BB
(69)
Vindesine
Diffuse Large B-Cell Lymphoma
The Affiliated Hospital of Xuzhou Medical University
P3
BB
(69)
Vosaroxin
Acute Myeloid Leukemia
University of Ulm
P3
BB
(69)
Zanubrutinib
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
P3
BB
(69)
Aav-Gad
Parkinson Disease
MeiraGTx, LLC
P2
BB
(69)
Adriamycin
Pancreatic Neoplasm
Northwell Health
P2
BB
(69)
Alcestobart
Non-Small Cell Lung Carcinoma
BeiGene
P2
BB
(69)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
Acute Leukemia
Masonic Cancer Center, University of Minnesota
P2
BB
(69)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
Fanconi Anemia
Porteus, Matthew, MD
P2
BB
(69)
Ap-Pa02
Pneumonia
Armata Pharmaceuticals, Inc.
P2
BB
(69)
Ap-Pa02
Pseudomonas Aeruginosa Infectious Disease
Armata Pharmaceuticals, Inc.
P2
BB
(69)
Bendamustine
Nodal Marginal Zone B-Cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
P2
BB
(69)
Bendamustine
Peripheral T-Cell Lymphoma, Not Otherwise Specified
The First Affiliated Hospital of Soochow University
P2
BB
(69)
Bendamustine
Burkitt Lymphoma
National Cancer Institute (NCI)
P2
BB
(69)
Bendamustine
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
UNC Lineberger Comprehensive Cancer Center
P2
BB
(69)
Bendamustine
Splenic Marginal Zone Lymphoma
UNC Lineberger Comprehensive Cancer Center
P2
BB
(69)
Bendamustine
T-Cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
P2
BB
(69)
Bet Bromodomain Inhibitor Zen-3694
Metastatic Prostate Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
P2
BB
(69)
Blinatumomab
B-Cell Adult Acute Lymphocytic Leukemia
Memorial Sloan Kettering Cancer Center
P2
BB
(69)
Bortezomib
Myelodysplastic Syndrome
Indiana University
P2
BB
(69)
Bortezomib
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Zhejiang Cancer Hospital
P2
BB
(69)
Bortezomib
Adult Acute Lymphoblastic Leukemia
Indiana University
P2
BB
(69)
Busulfanum
Acute Undifferentiated Leukemia
Ossium Health, Inc.
P2
BB
(69)
Busulfanum
Extranodal Nasal NK/T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
P2
BB
(69)
Showing 3151 to 3175 of 42,285 assets
Previous
Page 127 of 1692
Next